Would AstraZeneca really find itself contending with another megamerger offer, this time from Novartis? That’s the speculation on the street, despite signs…

Sanofi finally won FDA approval of its long-awaited GLP-1 diabetes drug Adlyxin. But “finally” is the operative word, and the med will have to scramble with…

Bristol-Myers Squibb came through in Q2 on both the sales and earnings fronts and raised guidance once again. But it wasn’t Opdivo and the usual suspects…

It’s a silver-lining quarter for AstraZeneca. Second-quarter sales slid--but not as far as market watchers expected--and new cancer meds, diabetes drugs and…

With billions in sales under biosimilar threat and facing investor pressure to make M&A moves, Amgen on Wednesday posted revenue and earnings beats for the…

The FDA stepped up warnings on antibiotics like Johnson & Johnson’s Levaquin, adding long-term risks to the drugs’ current black box. The drugs'…

GlaxoSmithKline CEO Andrew Witty is sitting pretty. For the second straight quarter, his much-maligned growth strategy has come through for the drugmaker,…

Bayer’s pharma lineup churned out growth for yet another quarter, racking up a 5.5% sales hike to €4.1 billion as the blood thinner Xarelto and vision med…

GlaxoSmithKline is not planning to exit the U.K. just because the U.K. is exiting the European Union. As if to emphasize its commitment, the drugmaker today…